js001
Showing 1 - 9 of 9
Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, JS001)
Not yet recruiting
- Muscle Invasive Bladder Carcinoma
- RC48-ADC
- JS001
-
Beijing, Beijing, China
- +2 more
Apr 2, 2022
Solid Tumor, Tumors, Malignant Tumor Trial in Changchun (ES102, JS001)
Recruiting
- Solid Tumor
- +2 more
- ES102
- JS001
-
Changchun, Jilin, ChinaJilin Cancer Hospital
Oct 28, 2021
Esophageal Small Cell Carcinoma Trial in Guangzhou (JS001, nab-paclitaxel, Cisplatin)
Recruiting
- Esophageal Small Cell Carcinoma
- JS001
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Dec 27, 2021
Head and Neck Squamous Cell Carcinoma Trial in Shanghai (postoperative radiotherapy, JS001)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- postoperative radiotherapy
- JS001
-
Shanghai, ChinaGuopei Zhu
Apr 12, 2021
Triple-Negative Breast Cancer Trial in China (JS001, Nab-Paclitaxel, Placebo)
Recruiting
- Triple-Negative Breast Cancer
- JS001
- +2 more
-
Beijing, Beijing, China
- +55 more
Sep 13, 2022
Colorectal Cancer Trial in Guangzhou (JS001, regorafenib tablet)
Unknown status
- Colorectal Cancer
- JS001
- regorafenib tablet
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 11, 2020
Colorectal Cancer Trial in Shanghai (JS001)
Unknown status
- Colorectal Cancer
- JS001
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Oct 5, 2019
Gastric Cancer, Locally Advanced Solid Tumor Trial in Guangzhou (JS001, Oxaliplatin, S1)
Recruiting
- Gastric Cancer
- Locally Advanced Solid Tumor
- JS001
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 5, 2020
Efficacy and Safety Trial in Guangzhou (JS001, Pemetrexed, Carboplatin)
Active, not recruiting
- Efficacy and Safety
- JS001
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Mar 12, 2019